Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
The UK's complex system of procuring medical technology for use in the NHS is being simplified. A new system will go live on May 8 under the Future Operating Model (FOM), an initiative that prioritizes outcomes-based rationales and allows for gain-sharing, while also targeting annual NHS savings. At this early stage, the device industry and health-care providers are both displaying a mix of optimism and skepticism.
Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat
The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.
Germany's center-left SPD party will be the junior partner in the new government after 66% of party members voted in favor of another coalition with the center-right Christian Union parties led by Angela Merkela. Jens Spahn, who is in Merkel's party but not in her inner circle, has already been given the health portfolio.
Coinciding with UK prime minister Theresa May's third major speech on her Brexit vision for the UK, the local medtech industry has taken the opportunity to stress the vital need for sensible, workable trading arrangements governing UK-EU health-care supply chains after March 2019.
UK diagnostics manufacturers face major challenges in adapting to the EU IVDR and to the possible changes that Brexit will bring in regulation, trading conditions, costs and access to talent. In addition, the industry will have to factor in a restructuring of pathology networks and future NHS procurement changes, all while transitioning to digital health-care concepts, says IVD industry association chief Doris-Ann Williams.
In the polarized environment of Washington DC, the US medtech industry was becoming increasingly concerned as 2017 turned to 2018 that the medical device sales tax would be reinstated after a two-year suspension. AdvaMed chairman Nadim Yared tells In Vivo about the efforts and lobbying that got Congressmen onside just in time – but the battle doesn’t stop there.